Angiogenesis Inhibitors

The Impact of Histological Types on the Efficacy of Angiogenesis Inhibitors in the Treatment of Advanced NSCLC: A Meta-Analysis of Randomized Controlled Trials

The Impact of Histological Types on the Efficacy of Angiogenesis Inhibitors in the Treatment of Advanced NSCLC: A Meta-Analysis of Randomized Controlled Trials

This research assesses the overall efficacy of angiogenesis inhibitor (AI)-containing regimens in the treatment of advanced non-small-cell lung cancer (NSCLC).

Breast cancer metastasis may be tied to cell that regulates blood flow

Breast cancer metastasis may be tied to cell that regulates blood flow

By

Scientists believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach for breast and other cancers.

Novel vaccine targets tumor angiogenesis, then creates a secondary immune response

By

A novel DNA vaccine is being employed to kill cancer, not by attacking tumor cells, but by targeting the blood vessels that keep them alive.

Angiogenesis Inhibitors (Fact Sheet)

Angiogenesis Inhibitors (Fact Sheet)

This fact sheet reviews the use of angiogenesis inhibitors to prevent the formation of new blood vessels, in order to stop or slow the growth or spread of cancerous tumors.

CT data help predict survival in metastatic melanoma

Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.

FDA Update - September/October 2012

News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).

Well-known antifungal drug shows promise against cancer

Thiabendazole, an antifungal drug in clinical use for 40 years, inhibits angiogenesis, slows tumor growth, and reduces vascular density of tumors.

VEGF blockade: Optimizing chemotherapy drug uptake

VEGF blockade: Optimizing chemotherapy drug uptake

By

New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.

Antiangiogenics could be effective against new ovarian cancer subtype

By

A newly identified subtype of ovarian cancer that builds its own blood vessels may be vulnerable to agents that block blood vessel formation.

Experimental agent slows progression of colorectal cancer

By

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.

Bevacizumab delays return of ovarian cancer

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.

LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication

The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.

Carefully consider and monitor bevacizumab use

Using bevacizumab in combination with chemotherapy or biological therapy raises the risk of treatment-related death—but the agent's potential benefits may outweigh the relatively low absolute risk.

Body's protein can stall tumor spread

A naturally occurring protein inhibits tumor growth and metastasis into secondary organs and has the potential to be developed into an anticancer drug, scientists have found.

New recommendations push for improved monitoring and control to limit cancer drug side effects

By

Doctors who monitor and help control a patient's blood pressure can minimize the side effects of novel cancer drugs, according to a paper published in the Journal of the National Cancer Institute (2010 May 5;102(9):596-604).

Vascular targeting in ovarian cancer: Therapeutic advances may improve the prognosis

Targeting tumor vasculature by inhibiting angiogenesis is a promising approach for women with advanced ovarian cancer, and clinical trials should designed to ensure that novel agents are evaluated rapidly

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs